{"analyses":[{"ciLowerLimit":"0.501","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.820","groupDescription":"TC2/3 or IC2/3-WT Population","groupIds":["OG000"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0004","pValueComment":"P-value is descriptive as it was not formally tested.","paramType":"Hazard Ratio (HR)","paramValue":"0.641","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.595","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.863","groupDescription":"TC1/2/3 or IC1/2/3-WT Population","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"0.0004","pValueComment":"P-value is descriptive as it was not formally tested.","paramType":"Hazard Ratio (HR)","paramValue":"0.716","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.5","upperLimit":"5.7","value":"5.5"},{"groupId":"OG001","lowerLimit":"5.6","upperLimit":"9.3","value":"7.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"162"},{"groupId":"OG001","value":"166"}],"units":"Participants"}],"title":"TC2/3 or IC2/3-WT Population"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.7","upperLimit":"5.7","value":"5.6"},{"groupId":"OG001","lowerLimit":"5.5","upperLimit":"7.3","value":"5.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}],"units":"Participants"}],"title":"TC1/2/3 or IC1/2/3-WT Population"}],"denoms":[{"counts":[{"groupId":"OG000","value":"277"},{"groupId":"OG001","value":"277"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization to the first occurrence of disease progression, as determined by the investigator with use of RECIST v1.1, or death from any cause, whichever occurs first. PFS could not be formally tested.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with non-squamous NSCLC will receive chemotherapy with pemetrexed in combination with either cisplatin or carboplatin (per investigator discretion) on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by maintenance therapy with pemetrexed alone as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).\n\nParticipants with squamous NSCLC will receive chemotherapy with gemcitabine on Days 1 and 8 of each 21-day cycle in combination with either cisplatin or carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles as per local standard of care, followed by best supportive care as per local standard of care until disease progression, unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG000","title":"Chemotherapy (Carboplatin/ Cisplatin) + (Pemetrexed/ Gemcitabine)"},{"description":"Participants with squamous or non-squamous NSCLC will receive atezolizumab on Day 1 of each 21-day cycle until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).","id":"OG001","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"Analysis was performed for the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT populations. Comparison of the treatment arms was performed in randomized participants who were selected on the basis of a minimum level of PD-L1 expression on tumor cells (TCs) and/or immune cells (ICs) with populations excluding participants with a sensitizing EGFR mutation or ALK translocation (i.e., wild type \\[WT\\]).","reportingStatus":"POSTED","timeFrame":"From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first until data cut-off on 4 February 2020 (up to approximately 54.5 months)","title":"Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations","type":"SECONDARY","unitOfMeasure":"Months"}